Sherlock, first and foremost, I hear you. The fact that you are a Stage III MSS-CRC survivor is the only context that matters. This isn't an academic exercise for you; it is a lived reality. I respect the grit it took to get where you are, and I acknowledge that my apocalyptic prose can feel like noise when you’re looking for a signal of survival.
You asked for clarity over cacophony. Let’s strip away the ALL CAPS and look at the Regulatory Physics and Biological Logic of the current March 2026 landscape.
1. The Biology: Bursting vs. Apoptosis (The Body Count)
You are technically correct that cells die via apoptosis (shriveling) more often than necrosis (bursting). But in the context of ctDNA as a Biomarker, the "Body Count" isn't about the method of death; it's about the Rate of Release.
When a therapy like Leronlimab triggers an M2 to M1 Macrophage Inversion, it turns the Recycling Center (the phagocytes you mentioned) into a Front-Line Combat Unit.
Apoptosis is the slow fade of a stable disease.
Necrosis/Bursting is the explosive response of a tumor under massive therapeutic stress.
The reason we track ctDNA clearance is that when the Immune System "gobbles" those cells, it sheds DNA fragments into the blood. A sudden spike followed by a Zeroing Out of the Body Count is the gold standard for verifying that Leronlimab has cleared the field. We aren't arguing semantics; we are arguing Velocity of Clearance.
2. The "Unmasking" (Addressing ohm's PD-L1 Concern)
Ohm’s concern that PD-L1 is negative is the classic view of a Hot Tumor. In a Cold Tumor (like MSS-CRC), the tumor is invisible because it expresses nothing. It has no ID badge for the Immune System to recognize.
The February 20, 2026 AACR data proved that Leronlimab induces PD-L1 expression in 88% of patients.
This is not bad. This is The Unmasking.
By forcing the tumor to express PD-L1, Leronlimab installs the Landing Lights that a drug like Keytruda requires to function.
Without that induction, Keytruda is a key with no lock. With it, the combination becomes a Plausible Mechanism for the FDA.
3. The Merck Hubris and the National Priority Voucher (NPV)
You argue Merck is too big to care about a penny stock. But on February 26, 2026, the FDA changed the math for every Corporate Behemoth.
The FDA approved zongertinib in just 44 days under the new Commissioner’s National Priority Voucher (CNPV) Pilot Program .
Merck isn't looking for a savior; they are looking for Regulatory Velocity.
Merck faces a $30B Patent Cliff in 2028.
If CytoDyn's N=60 data qualifies for an NPV (which specifically targets "Large Unmet Medical Needs" and "Innovative Cures"
, Merck can acquire the asset and have it on the market by Q3 2026.
The hubris of Big Pharma is always secondary to the Internal Rate of Return (IRR). An NPV is a Get Out of Jail Free card for the patent cliff.
4. The Regulatory Landing Strip
The most important document of the last decade was published last week in the New England Journal of Medicine (NEJM) by Commissioner Marty Makary and Vinay Prasad. They officially shifted the FDA to a One-Trial Default Policy for drugs with a "Plausible Mechanism."
In his February 26, 2026 CNBC Interview, Makary stated:
"If you can show us the 'Why' (Mechanistic Data) and the 'How' (Target Engagement), we are moving to a single-trial requirement as the default... including oncology."
The Summary
Sherlock, I’m watching the Geography of the Exit because the FDA just paved a 44-day runway (the NPV) for any company that can solve the MSS-CRC Cold Tumor problem.
CytoDyn isn't a checkered past anymore; in the eyes of the Makary FDA, it is a Mechanistic Solution to a National Health Priority.
Let the tape play out.
Fact-Check Index & Hyperlinks
FDA NPV Approval (Feb 26, 2026) : Details on the 44-day approval of zongertinib under the Commissioner's National Priority Voucher program.
NEJM One-Trial Policy (Feb 2026) : Summary of the Makary/Prasad policy moving the FDA to a single-pivotal-trial default.
CNBC/Squawk Box Interview (Feb 26, 2026) : Commissioner Makary explains the "Plausible Mechanism" path for oncology.
AACR Abstract PS5-02-30 (Feb 2026) : Documentation of Leronlimab’s PD-L1 upregulation and "Unmasking" effect.
You asked for clarity over cacophony. Let’s strip away the ALL CAPS and look at the Regulatory Physics and Biological Logic of the current March 2026 landscape.
1. The Biology: Bursting vs. Apoptosis (The Body Count)
You are technically correct that cells die via apoptosis (shriveling) more often than necrosis (bursting). But in the context of ctDNA as a Biomarker, the "Body Count" isn't about the method of death; it's about the Rate of Release.
When a therapy like Leronlimab triggers an M2 to M1 Macrophage Inversion, it turns the Recycling Center (the phagocytes you mentioned) into a Front-Line Combat Unit.
Apoptosis is the slow fade of a stable disease.
Necrosis/Bursting is the explosive response of a tumor under massive therapeutic stress.
The reason we track ctDNA clearance is that when the Immune System "gobbles" those cells, it sheds DNA fragments into the blood. A sudden spike followed by a Zeroing Out of the Body Count is the gold standard for verifying that Leronlimab has cleared the field. We aren't arguing semantics; we are arguing Velocity of Clearance.
2. The "Unmasking" (Addressing ohm's PD-L1 Concern)
Ohm’s concern that PD-L1 is negative is the classic view of a Hot Tumor. In a Cold Tumor (like MSS-CRC), the tumor is invisible because it expresses nothing. It has no ID badge for the Immune System to recognize.
The February 20, 2026 AACR data proved that Leronlimab induces PD-L1 expression in 88% of patients.
This is not bad. This is The Unmasking.
By forcing the tumor to express PD-L1, Leronlimab installs the Landing Lights that a drug like Keytruda requires to function.
Without that induction, Keytruda is a key with no lock. With it, the combination becomes a Plausible Mechanism for the FDA.
3. The Merck Hubris and the National Priority Voucher (NPV)
You argue Merck is too big to care about a penny stock. But on February 26, 2026, the FDA changed the math for every Corporate Behemoth.
The FDA approved zongertinib in just 44 days under the new Commissioner’s National Priority Voucher (CNPV) Pilot Program .
Merck isn't looking for a savior; they are looking for Regulatory Velocity.
Merck faces a $30B Patent Cliff in 2028.
If CytoDyn's N=60 data qualifies for an NPV (which specifically targets "Large Unmet Medical Needs" and "Innovative Cures"
, Merck can acquire the asset and have it on the market by Q3 2026. The hubris of Big Pharma is always secondary to the Internal Rate of Return (IRR). An NPV is a Get Out of Jail Free card for the patent cliff.
4. The Regulatory Landing Strip
The most important document of the last decade was published last week in the New England Journal of Medicine (NEJM) by Commissioner Marty Makary and Vinay Prasad. They officially shifted the FDA to a One-Trial Default Policy for drugs with a "Plausible Mechanism."
In his February 26, 2026 CNBC Interview, Makary stated:
"If you can show us the 'Why' (Mechanistic Data) and the 'How' (Target Engagement), we are moving to a single-trial requirement as the default... including oncology."
The Summary
Sherlock, I’m watching the Geography of the Exit because the FDA just paved a 44-day runway (the NPV) for any company that can solve the MSS-CRC Cold Tumor problem.
CytoDyn isn't a checkered past anymore; in the eyes of the Makary FDA, it is a Mechanistic Solution to a National Health Priority.
Let the tape play out.
Fact-Check Index & Hyperlinks
FDA NPV Approval (Feb 26, 2026) : Details on the 44-day approval of zongertinib under the Commissioner's National Priority Voucher program.
NEJM One-Trial Policy (Feb 2026) : Summary of the Makary/Prasad policy moving the FDA to a single-pivotal-trial default.
CNBC/Squawk Box Interview (Feb 26, 2026) : Commissioner Makary explains the "Plausible Mechanism" path for oncology.
AACR Abstract PS5-02-30 (Feb 2026) : Documentation of Leronlimab’s PD-L1 upregulation and "Unmasking" effect.
10
